

U.S. Patent Application Serial No. 09/489,711
Attorney Docket No. 3153.00050/PC10299A

AMENDED VERSION

IN THE CLAIMS:

Claim 1-12 (Cancelled)

13. (Currently Amended) An antigen composition comprising an *E. rhusiopathiae* culture fluid fraction and a stabilizing agent, ~~wherein the stabilizing agent is a metal hydroxide, a metal phosphate, an aluminum hydroxide gel, a calcium phosphate gel, a zinc hydroxide/calcium hydroxide gel or an alum~~ wherein the composition is stable at 2°C to 8°C for at least one year and provides immunity to weaned pigs for at least six months.

14. (Previously Amended) The antigen composition of Claim 13, wherein the *E. rhusiopathiae* culture is inactivated.

15. (Previously Amended) The antigen composition of Claim 13, wherein the *E. rhusiopathiae* culture is inactivated with formalin or with beta propiolactone.

16. (Currently Amended) The antigen composition of Claim 13, wherein the fluid fraction is concentrated 6 to 20X fold.

17. (Currently Amended) A vaccine composition comprising:

(1) an *E. rhusiopathiae* antigen composition; ~~and,~~

U.S. Patent Application Serial No. 09/489,711
Attorney Docket No. 3153.00050/PC10299A

~~(2) an adjuvant composition,~~

~~wherein the antigen composition comprises an comprising a 10 fold concentrated fluid fraction from an *E. rhusiopathiae* culture fluid fraction that is inactivated with formalin or beta propiolactone and about 30% volume by volume (v/v) aluminum hydroxide gel as a stabilizing agent, wherein the stabilizing agent is a metal hydroxide, a metal phosphate, an aluminum hydroxide gel, a calcium phosphate gel, a zinc hydroxide/calcium hydroxide gel or an alum; and~~

(2) an adjuvant comprising 10% lecithin in mineral oil, 5.6% polysorbate and 2.4% sorbitan monooleate in phosphate buffered saline, wherein the vaccine composition is stable at 2°C to 8°C for at least one year and provides immunity to weaned pigs for at least six months.

Claim 18 (Cancelled)

Claims 19-23 (Withdrawn)

Claims 24-29 (Cancelled)

30. (Currently Amended) A vaccine composition comprising:

(1) an antigen composition aluminum hydroxide gel used as a stabilizing agent; and,

U.S. Patent Application Serial No. 09/489,711
Attorney Docket No. 3153.00050/PC10299A

(2) an adjuvant composition,
wherein the antigen composition comprises an *E. rhusiopathiae* culture fluid
fraction ~~and a stabilizing agent wherein the stabilizing agent is aluminum~~
~~hydroxide gel; and~~, wherein the adjuvant composition comprises about 2%
v/v lecithin, about 18% v/v mineral oil, and about 5.6% v/v ~~Tween~~
~~80~~polysorbate and about 2.4% v/v ~~Span-80~~sorbitan monooleate with the
remaining volume being a saline solution.